Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

More forecast upgrades possible at Entain, says Shore Capital

(Sharecast News) - Shore Capital has kept a 'buy' rating on Entain following the company's raised guidance for its BetMGM operations, suggesting that there could be more upgrades to come at the sports betting and gambling group. The company, which owns a 50% share of the US joint venture BetMGM with MGM Resorts, said net revenue growth (NGR) in the second quarter so far was consistent with the 34% year-on-year surge seen in the first three months of the year.

As a result, BetMGM revenues are now expected to be "at least $2.6bn", up from the previous $2.4bn-2.5bn range, and EBITDA is forecast to be "at least $100m", compared with earlier guidance of above breakeven.

Shore Capital said that, after such a strong first quarter, an upgrade to full-year NGR was to be expected, and while comparatives get tougher in the second half, "a beat to the $2.6bn is likely".

Entain said the trading momentum at BetMGM reinforces its confidence in future growth prospects and its $500m EBITDA target for the division in the coming years - something that Shore Capital said isn't yet reflected in the current share price.

"Entain trades on a current year PER of 15x and an EV/EBITDA of c7.5x excluding BetMGM. Valuing BetMGM at c2-3x NGR would value "core" Entain on a single-digit PER. The current valuation failing to reflect the improving trends at both "core" Entain and its 50% stake in BetMGM. BUY," the broker said.

Entain shares were up 13.6% at 853.2p by 1449 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.